ADMA Biologics Inc (ADMA): Price and Financial Metrics

ADMA Biologics Inc (ADMA)

Today's Latest Price: $2.84 USD

0.07 (-2.41%)

Updated May 22 4:00pm

Add ADMA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ADMA Stock Summary

  • With a price/sales ratio of 6.81, Adma Biologics Inc has a higher such ratio than 84.1% of stocks in our set.
  • Revenue growth over the past 12 months for Adma Biologics Inc comes in at 118.68%, a number that bests 95.37% of the US stocks we're tracking.
  • Adma Biologics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -72.19%, greater than the shareholder yield of merely 6.74% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Adma Biologics Inc are DPW, ELGX, TTMI, NESR, and SWM.
  • ADMA's SEC filings can be seen here. And to visit Adma Biologics Inc's official web site, go to
ADMA Daily Price Range
ADMA 52-Week Price Range

ADMA Stock Price Chart More Charts

ADMA Price/Volume Stats

Current price $2.84 52-week high $5.48
Prev. close $2.91 52-week low $1.45
Day low $2.76 Volume 2,277,113
Day high $2.96 Avg. volume 2,419,066
50-day MA $2.73 Dividend yield N/A
200-day MA $3.82 Market Cap 245.22M

ADMA Biologics Inc (ADMA) Company Bio

ADMA Biologics, Inc. develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company was founded in 2004 and is based in Ramsey, New Jersey.

ADMA Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ADMA Latest Social Stream

Loading social stream, please wait...

View Full ADMA Social Stream

Latest ADMA News From Around the Web

Below are the latest news stories about Adma Biologics Inc that investors may wish to consider to help them evaluate ADMA as an investment opportunity.

ADMA Biologics Inc (ADMA) Q1 2020 Earnings Call Transcript

At this time, I would like to introduce Mr. Sam Martin, Managing Director at Argot Partners, ADMA's Investor Relations firm. Welcome everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the first quarter 2020.

Yahoo | May 7, 2020

Edited Transcript of ADMA earnings conference call or presentation 6-May-20 8:30pm GMT

Q1 2020 ADMA Biologics Inc Earnings Call

Yahoo | May 7, 2020

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate plasma.

Yahoo | May 7, 2020

ADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments

RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,.

Yahoo | May 7, 2020

Adma Biologics (ADMA) Reports Q1 Loss, Misses Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 7, 2020

Read More 'ADMA' Stories Here

ADMA Price Returns

1-mo -7.19%
3-mo -14.71%
6-mo -39.70%
1-year -38.26%
3-year -28.82%
5-year -66.82%
YTD -29.00%
2019 67.36%
2018 -25.55%
2017 -37.30%
2016 -36.56%
2015 -27.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8177 seconds.